title: Drugs for stroke: action of nitrone (Z)-N-(2-bromo-5-hydroxy-4-methoxybenzylidene)-2-methylpropan-2-amine oxide on rat cortical neurons in culture subjected to oxygen-glucose-deprivation.
abstract: The action of (Z)-N-(2-bromo-5-hydroxy-4-methoxybenzylidene)-2-methylpropan-2-amine oxide (RP6) on rat cortical neurons in culture, under oxygen-glucose-deprivation conditions, is reported. Cortical neurons in culture were treated during 1 h with OGD. After, they were placed under normal conditions during 24 h (reperfusion) in absence and presence of RP6. Different parameters were measured under each condition (control, 1 h OGD and 1 h OGD + reperfusion in absence and presence of RP6). RP6 protects neurons against ROS generation, lipid peroxidation levels, LDH release and mitochondrial membrane potential alteration, when administered during reperfusion after the OGD damage. Consequently, these results show that nitrone RP6 protects cells against ischemia injury produced during the reoxygenation, and could be a potential drug for the ictus therapy.
authors.affiliation: Departamento de Bioquímica y Biología Molecular II, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Arce
authors.forename: Sabela
authors.initials: S
authors.lastname: Diaz-Castroverde
authors.forename: María J
authors.initials: MJ
authors.lastname: Canales
authors.forename: José
authors.initials: J
authors.lastname: Marco-Contelles
authors.forename: Abdelouahid
authors.initials: A
authors.lastname: Samadi
authors.forename: María J
authors.initials: MJ
authors.lastname: Oset-Gasque
authors.forename: María P
authors.initials: MP
authors.lastname: González
mesh_terms: D000818:Animals; D001597:Benzylidene Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000166:cytology*; D053148:Caspase 3 / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D005947:Glucose / Q000172:deficiency*; D006139:Guaiacol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D007097:Imines / Q000494:pharmacology* / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D010100:Oxygen / Q000378:metabolism*; D011247:Pregnancy; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D020521:Stroke / Q000188:drug therapy*
chemical_list: D001597:Benzylidene Compounds; D007097:Imines; C577438:N-(2-bromo-5-hydroxy-4-methoxybenzylidene)-2-methylpropan-2-amine oxide; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; D006139:Guaiacol; D007770:L-Lactate Dehydrogenase; D053148:Caspase 3; D005947:Glucose; D010100:Oxygen